Corey Obrien, DO
Pulmonary Disease · Lansing, MINPI 1437321213
Payments from drug & device makers
Across 462 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$2K
- Grifols USA, LLC$1K
- Boehringer Ingelheim$1K
- GSK$846
- Regeneron Healthcare Solutions, Inc.$573
- plus $3K from 29 others
What the payments were for
- Consulting fees$1251%
- Food & beverage$8,27656%
- Education$6,25843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $6,017 |
| AstraZeneca(2 entities) | 96 | $1,883 |
| Grifols USA, LLC | 69 | $1,240 |
| Boehringer Ingelheim | 55 | $1,120 |
| GSK | 57 | $846 |
| Regeneron Healthcare Solutions, Inc. | 29 | $573 |
| Sanofi | 34 | $567 |
| Mylan Specialty L.p. | 19 | $381 |
| Insmed, Inc. | 25 | $366 |
| Jazz Pharmaceuticals Inc. | 10 | $235 |
| Bayer | 4 | $184 |
| Actelion Pharmaceuticals US, Inc. | 5 | $142 |
| Merck | 7 | $125 |
| United Therapeutics Corporation | 4 | $99 |
| Viatris Specialty LLC | 5 | $99 |
| Genentech USA, Inc. | 5 | $80 |
| Verona Pharma, Inc. | 4 | $78 |
| Inspire Medical Systems, Inc. | 1 | $76 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $62 |
| Philips North America LLC | 4 | $62 |
| Harmony Biosciences LLC | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Amgen | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Electromed, Inc. | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Resmed Corp | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Covidien LP | 1 | $13 |
| Pulmonx Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,659 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 64 | $855,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 194 | $192,829 |
| XolairOmalizumab | 40 | $163,899 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $119,388 |
| NucalaMepolizumab | 24 | $88,218 |
| Dupixent SyringeDupilumab | 23 | $82,879 |
| Dupixent PenDupilumab | 13 | $59,227 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $46,533 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $35,043 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $31,563 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $27,944 |
| Spiriva RespimatTiotropium Bromide | 32 | $21,145 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $14,361 |
| DuleraMometasone/Formoterol | 28 | $13,519 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,120 | $911,627146 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $846 | $360,910373 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,883 | $45,92480 claims |
| MerckDulera | $125 | $13,51928 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $54 | $3,52413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Lansing
- Jennifer ElyLansing$37K
- David YoungLansing$36K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.